Zealand's ZUPREME-2 petrelintide trial is marked completed

A Phase 2 study of petrelintide called ZUPREME-2 has moved from "active, not recruiting" to "completed" in its federal clinical trial registry listing, according to a same-day registry entry dated September 9, 2026 ^[1]. The trial, formally titled "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes," is sponsored by Zealand Pharma and is registered under trial number NCT06926842 ^[1]. The status change means the study has finished its planned procedures with participants.

Petrelintide is an amylin analogue, a class of drug that works differently from GLP-1 medicines like semaglutide and tirzepatide ^[2]. Zealand co-develops the drug with Roche under a partnership announced in 2025 worth up to roughly $5.3 billion, including $1.65 billion paid upfront, with the rest tied to development and sales milestones ^[2]. Zealand reported having about $2.1 billion in cash as of a mid-2026 snapshot ^[2].

In earlier Phase 2 testing, petrelintide showed weight loss of up to 10.7% over 42 weeks, a smaller effect than the roughly 15% to 28% ranges reported for some GLP-1 and multi-hormone drugs in development ^[2]. Its selling point in industry tracking has been tolerability rather than maximum weight loss: reports describe the drug's side-effect profile as close to placebo, with no vomiting reported in the group that received the highest effective dose ^[2]. For comparison, Novo Nordisk's amylin-containing combination drug CagriSema produced about 22.7% weight loss in its own trials, below the roughly 25% investors had expected ^[2].

The sources available do not specify an exact date for when Zealand will release the ZUPREME-2 topline results, nor do they detail how this trial's data will feed into any larger, registrational study design. Those specifics are not yet confirmed in the registry data or company materials reviewed here.

Why it matters for patients

Petrelintide is not an approved medicine. It has not gone through the type of large, late-stage testing that FDA reviewers require before a drug can be sold to the public. The completion of this one Phase 2 study is a procedural milestone, not a green light for use.

Still, the drug is being watched because of its mechanism and its side-effect profile. Amylin analogues work on a different hormone pathway than GLP-1 drugs, and if petrelintide's tolerability holds up in larger trials, it could eventually offer an option for people who stop GLP-1 treatment because of nausea or vomiting. That would matter most for patients who have tried semaglutide or tirzepatide and could not tolerate the gastrointestinal side effects, or for people managing both excess weight and type 2 diabetes who want more options.

The tradeoff so far reported is real: petrelintide's weight-loss numbers are smaller than those seen with tirzepatide or some newer combination drugs in testing ^[2]. Patients considering GLP-1 or related therapies today should know that petrelintide remains years away, at best, from being an approved alternative, and any comparison of effectiveness or side effects should wait for larger, controlled studies.

What happens next

Zealand and Roche have separately said they plan to start a Phase 2 study combining petrelintide with another drug, enicepatide, sometime in the second half of 2026, according to an industry catalyst calendar ^[2]. Beyond that, the sources reviewed do not give a confirmed date for when full ZUPREME-2 results will be published or presented, or what the next formal step for petrelintide's development program will be. That information is not yet known from the materials available.